FlowMedica was purchased by AngioDynamics. Study will be re-started by AngioDynamics.

This is a prospective, observational, multi-center study with consecutive enrollment. Up to 1,000 patients will be enrolled. The objective of this post-marketing surveillance study is to collect clinical usage patterns of the Benephit Infusion Systems. As a result, FlowMedica will be able to:

1. Better understand and quantify usage patterns including patient characteristics, adjunctive procedures, and infusion agents.
2. Collect user-interface information and overall customer satisfaction.
3. Monitor post-marketing device performance.

Inclusion Criteria:

• Exposure to one or more components of the Benephit Infusion System
• Ability to give written informed consent

Exclusion Criteria:

• Inclusion in another clinical study that may affect usage of the Benephit system

Hospitalized patients in whom one or more components of the Benephit Infusion System are planned to be used.